Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277


Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.

Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D.

AIDS. 2005 Jun 10;19(9):917-25.


Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.


Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, Wakeford JH, Snidow JW, Shachoy-Clark AD, Fleming JW, Pakes GE, Hernandez JE; ESS40003 Study Team.

BMC Infect Dis. 2005 Jan 12;5:2.


Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.

N Engl J Med. 2003 Sep 11;349(11):1036-46.


Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.


Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P.

PLoS Med. 2004 Oct;1(1):e19. Epub 2004 Oct 19. Erratum in: PLoS Med. 2004 Dec;1(3):e73.


Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team.

AIDS. 2005 Sep 2;19(13):1385-91.


Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Feb;8(1):27-35.


The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.

Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S.

HIV Med. 2005 May;6(3):179-84.


HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA; PIILR Study Group.

AIDS. 2001 Sep 28;15(14):1811-22.


Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM.

AIDS. 1999 May 7;13(7):805-10.


Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):34-42.


Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B.

AIDS. 2002 Jul 5;16(10):1383-9.


Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J.

AIDS. 2000 May 5;14(7):807-12.


Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Clin Infect Dis. 2007 Jan 1;44(1):120-7. Epub 2006 Nov 16.


Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.

Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, Chiodo F.

AIDS. 2005 Jul 1;19(10):1051-8.


Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).

Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):540-50.


Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.


Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.

Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A, Borkowf CB, Ndazima V, Brooks JT.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11.


Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2011 Aug;66(8):1869-77. doi: 10.1093/jac/dkr208. Epub 2011 Jun 1.

Items per page

Supplemental Content

Write to the Help Desk